Authors
Belén Pérez-Pevida, Mónica Santana Santana, Cristina Liaño Arriola, Alfonso Maldonado, Beatriz Clérigo, Cristina Ruiz, Cecilia Higueruela, María D Ballesteros-Pomar, Irene Bretón Lesmes, Manuela Moreira Rodríguez
Published in
Clinical nutrition ESPEN. Pages 105005. Aug 01, 2026. Epub Aug 01, 2026.
Abstract
Recent randomised controlled trials have demonstrated the efficacy of tirzepatide in inducing weight loss among adults with overweight or obesity, irrespective of diabetes mellitus status. However, evidence from real-world settings remains limited. This study aimed to evaluate the effectiveness and safety of tirzepatide for weight management in routine clinical practice.
This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions. The primary outcomes were changes in body weight and body composition after 6 months of treatment. Secondary assessments included anthropometric and cardiometabolic parameters, quality of life, and tolerability.
The median tirzepatide dose at 6 months was 7.5 mg. At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved ≥15%. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%.
This prospective real-world study confirms the effectiveness and safety of tirzepatide for weight management, even at maintenance doses lower than the approved dose, and supports findings from randomised clinical trials.
PMID:
42542297
Bibliographic data and abstract were imported from PubMed on 02 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0